Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide
in patients after allogeneic stem cell transplantation, accomplished in two institutions
(University Medical Center Hamburg-Eppendorf/ University Medical Center Heidelberg).